Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
16th patient dosed with IMX-110 to date This is the second patient dosed with IMX-110 in December 2022 Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical data expected to be released on a rolling basis beginning in Q1 2023 LOS ANGELES, CA, Dec. 20, 2022 — Immix […]